Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update
The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update“ provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 16 bln in 2016. Sales of anti-VEGF ophthalmic products continue to rise, while Avastin has come to an inflection point, also by the first approval of an Avastin biosimilar by the FDA.
The forthcoming patent expiries in the major markets have attracted a number of companies with global development of Avastin biosimilars in advanced clinical stages.
So far, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies, proteins or vaccines for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update“ provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 16 bln in 2016. Sales of anti-VEGF ophthalmic products continue to rise, while Avastin has come to an inflection point, also by the first approval of an Avastin biosimilar by the FDA.
The forthcoming patent expiries in the major markets have attracted a number of companies with global development of Avastin biosimilars in advanced clinical stages.
So far, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies, proteins or vaccines for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
ONCOLOGY
1) MARKETED PRODUCTS IN ONCOLOGY
Avastin, Zaltrap & Cyramza Sales 2008 – 2016
Avastin Sales & Indication Portfolio
Zaltrap Sales & Indication
Cyramza Sales & Indication Portfolio
2) BIOSUPERIORS IN ONCOLOGY
Anti-VEGF Biosuperiors of Avastin
Bispecific Anti-VEGF Biosuperiors of Avastin
Bispecific Anti-VEGF Proteins
Anti-VEGF-R Biosuperiors of Cyramza
Anti-VEGF-R Vaccines
Bispecific Anti-VEGF-R Biosuperiors of Cyramza
3) BIOSIMILARS IN ONCOLOGY
Avastin Biosimilars in Global Development
Avastin Biosimilar Developments in Less Regulated Markets
Avastin Biosimilar Developments in Early Stages
OPHTHALMOLOGY
4) MARKETED PRODUCTS IN OPHTHALMOLOGY
Lucentis & Eylea Sales 2008 – 2016
Eylea Sales & Indication Portfolio
Lucentis Sales & Indication Portfolio
Lang Mu Sales & Indication Portfolio
5) BIOSUPERIORS IN OPHTHALMOLOGY
Antibody-Mediated Anti-VEGF Biosuperiors in Ophthalmology
Other Anti-VEGF Biosuperiors in Ophthalmology
6) BIOSIMILARS IN OPHTHALMOLOGY
Lucentis Biosimilars
Eylea Biosimilars
1) MARKETED PRODUCTS IN ONCOLOGY
Avastin, Zaltrap & Cyramza Sales 2008 – 2016
Avastin Sales & Indication Portfolio
Zaltrap Sales & Indication
Cyramza Sales & Indication Portfolio
2) BIOSUPERIORS IN ONCOLOGY
Anti-VEGF Biosuperiors of Avastin
Bispecific Anti-VEGF Biosuperiors of Avastin
Bispecific Anti-VEGF Proteins
Anti-VEGF-R Biosuperiors of Cyramza
Anti-VEGF-R Vaccines
Bispecific Anti-VEGF-R Biosuperiors of Cyramza
3) BIOSIMILARS IN ONCOLOGY
Avastin Biosimilars in Global Development
Avastin Biosimilar Developments in Less Regulated Markets
Avastin Biosimilar Developments in Early Stages
OPHTHALMOLOGY
4) MARKETED PRODUCTS IN OPHTHALMOLOGY
Lucentis & Eylea Sales 2008 – 2016
Eylea Sales & Indication Portfolio
Lucentis Sales & Indication Portfolio
Lang Mu Sales & Indication Portfolio
5) BIOSUPERIORS IN OPHTHALMOLOGY
Antibody-Mediated Anti-VEGF Biosuperiors in Ophthalmology
Other Anti-VEGF Biosuperiors in Ophthalmology
6) BIOSIMILARS IN OPHTHALMOLOGY
Lucentis Biosimilars
Eylea Biosimilars
